These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 26793974)

  • 1. A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer.
    Akaza H; Uemura H; Tsukamoto T; Ozono S; Ogawa O; Sakai H; Oya M; Namiki M; Fukasawa S; Yamaguchi A; Uemura H; Ohashi Y; Maeda H; Saito A; Takeda K; Naito S
    Int J Clin Oncol; 2016 Aug; 21(4):773-782. PubMed ID: 26793974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
    Teply BA; Wang H; Luber B; Sullivan R; Rifkind I; Bruns A; Spitz A; DeCarli M; Sinibaldi V; Pratz CF; Lu C; Silberstein JL; Luo J; Schweizer MT; Drake CG; Carducci MA; Paller CJ; Antonarakis ES; Eisenberger MA; Denmeade SR
    Lancet Oncol; 2018 Jan; 19(1):76-86. PubMed ID: 29248236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study.
    Nagahara A; Uemura M; Sato M; Nakata W; Tsujihata M; Takao T; Matsumura S; Nishimura K; Takada S; Iwanishi T; Kobayashi Y; Ishizuya Y; Takada T; Okada K; Inoue H; Kato T; Hatano K; Kawashima A; Ujike T; Fujita K; Nonomura N
    Jpn J Clin Oncol; 2024 May; 54(5):584-591. PubMed ID: 38305451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
    Altavilla A; Casadei C; Lolli C; Menna C; Ravaglia G; Gurioli G; Farolfi A; Brighi N; Conteduca V; Burgio SL; Schepisi G; Rossi L; Gargiulo S; Lisotti I; De Giorgi U
    Expert Opin Pharmacother; 2020 Dec; 21(17):2091-2099. PubMed ID: 32783772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.
    Higano CS; Beer TM; Taplin ME; Efstathiou E; Hirmand M; Forer D; Scher HI
    Eur Urol; 2015 Nov; 68(5):795-801. PubMed ID: 25698064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Enzalutamide-a novel androgen receptor inhibitor that provides treatment options for patients with castration-resistant prostate cancer].
    Maeda H; Saito A
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):805-10. PubMed ID: 25131864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer.
    Kim CS; Choi YD; Lee SE; Lee HM; Ueda T; Yonese J; Fukagai T; Chiong E; Lau W; Abhyankar S; Theeuwes A; Tombal B; Beer TM; Kimura G
    Medicine (Baltimore); 2017 Jul; 96(27):e7223. PubMed ID: 28682871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.
    Bianchini D; Lorente D; Rodriguez-Vida A; Omlin A; Pezaro C; Ferraldeschi R; Zivi A; Attard G; Chowdhury S; de Bono JS
    Eur J Cancer; 2014 Jan; 50(1):78-84. PubMed ID: 24074764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study).
    Iguchi T; Tamada S; Kato M; Yasuda S; Yamasaki T; Nakatani T
    BMC Cancer; 2019 Apr; 19(1):339. PubMed ID: 30971225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial.
    Cella D; Ivanescu C; Holmstrom S; Bui CN; Spalding J; Fizazi K
    Ann Oncol; 2015 Jan; 26(1):179-185. PubMed ID: 25361992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
    Penson DF; Armstrong AJ; Concepcion R; Agarwal N; Olsson C; Karsh L; Dunshee C; Wang F; Wu K; Krivoshik A; Phung D; Higano CS
    J Clin Oncol; 2016 Jun; 34(18):2098-106. PubMed ID: 26811535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzalutamide in Japanese patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial.
    Kimura G; Yonese J; Fukagai T; Kamba T; Nishimura K; Nozawa M; Mansbach H; Theeuwes A; Beer TM; Tombal B; Ueda T
    Int J Urol; 2016 May; 23(5):395-403. PubMed ID: 27018069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.
    Graff JN; Baciarello G; Armstrong AJ; Higano CS; Iversen P; Flaig TW; Forer D; Parli T; Phung D; Tombal B; Beer TM; Sternberg CN
    Ann Oncol; 2016 Feb; 27(2):286-94. PubMed ID: 26578735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzalutamide: a review of its use in metastatic, castration-resistant prostate cancer.
    Sanford M
    Drugs; 2013 Oct; 73(15):1723-32. PubMed ID: 24127223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
    Chen WS; Aggarwal R; Zhang L; Zhao SG; Thomas GV; Beer TM; Quigley DA; Foye A; Playdle D; Huang J; Lloyd P; Lu E; Sun D; Guan X; Rettig M; Gleave M; Evans CP; Youngren J; True L; Lara P; Kothari V; Xia Z; Chi KN; Reiter RE; Maher CA; Feng FY; Small EJ; Alumkal JJ;
    Eur Urol; 2019 Nov; 76(5):562-571. PubMed ID: 30928160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study.
    Iguchi T; Tamada S; Kato M; Yasuda S; Machida Y; Ohmachi T; Ishii K; Iwata H; Yamamoto S; Kanamaru T; Morimoto K; Hase T; Tashiro K; Harimoto K; Deguchi T; Adachi T; Iwamoto K; Takegaki Y; Nakatani T
    Int J Clin Oncol; 2020 Mar; 25(3):486-494. PubMed ID: 31564004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.
    Pezaro CJ; Omlin AG; Altavilla A; Lorente D; Ferraldeschi R; Bianchini D; Dearnaley D; Parker C; de Bono JS; Attard G
    Eur Urol; 2014 Sep; 66(3):459-65. PubMed ID: 24411987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.
    Armstrong AJ; Halabi S; Healy P; Alumkal JJ; Winters C; Kephart J; Bitting RL; Hobbs C; Soleau CF; Beer TM; Slottke R; Mundy K; Yu EY; George DJ
    Eur J Cancer; 2017 Aug; 81():228-236. PubMed ID: 28502694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
    van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.